Meta-analysis On Safety Of Ramucirumab Involved Regimen For Advanced Solid Tumors

Aim:To compare the safety of ramucirumab involved regimen and non-ramucirumab involved regimen for advanced solid tumors by meta-analysis.Methods:Databases including Pubmed, Cochrane Library, EMBase, Clinical Trials.gov databases, Wanfang, CNKI and VIP were searched. Randomized controlled trials(RCTs) focusing on ramucirumab involved regimen for advanced solid tumors were collected. All the literatures retrieved were screened according to inclusion and exclusion criteria. The software Rev Man5.3 was used for meta-analysis. The outcomes included adverse effect(grade ≥3).Results:Seven RCTs with 6 different types of malignancies and 5 194 patients were included in this meta-analysis. The results of meta-analysis suggested that the grade ≥3 toxicity analysis showed significant differences between the 2 groups in hypertension(RR=3.75, 95%CI:2.83-4.96, P<0.000 01), gastrointestinal perforation(RR=3.37, 95%CI:1.51-7.54, P=0.003). However, There were no significant differences in diarrhea(RR=1.30,95%CI:0.98-1.73,P=0.70),venous thromboembolism(RR=0.78, 95%CI:0.55-1.10, P=0.16), arterial thromboembolism(RR=1.07,95%CI :0.61-1.88,P=0.81), bleeding/hemorrhage(RR=1.07,95%CI:0.77-1.48,P=0.70).Conclusion : Compared with non-ramucirumab involved regimen, ramucirumab involved regimen can increase incidence of the grade≥3 toxicity in patients with advanced solid tumors. The relative risk of hypertension and gastrointestinal perforation increase 2.75 times and 2.37 times without raising risk of diarrhea, venous thromboembolism, arterial thromboembolism, bleeding/hemorrhage.